Healing from within
Conquering lymphatic disorders, restoring the body’s immune system
Latest News
Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Multi-site clinical study to evaluate BioBridge®as prophylactic treatment for at-risk patients UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first...
Fibralign Announces CE Mark Approval for BioBridge®
European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...
Fibralign Announces Strategic Partnership with Terumo
Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...
About Us
Fibralign is an award-winning, commercial-stage Stanford-spinout that produces novel therapeutic biomedical devices that are designed to address major unmet medical needs.
The company has launched its first product, the BioBridge Collagen Matrix, which has now been used in over 750 surgeries by leading surgeons in 19 countries for the treatment of secondary lymphedema, a global chronic disease that currently has no cure.
BioBridge® Collagen Matrix
- BioBridge is a novel thread-like scaffold that has been shown in preclinical and clinical studies to repair damaged lymphatic tissue.
- FDA 510(k) cleared Class II device* for use in soft tissue repair.
- CE mark approved, Class III device for surgical treatment of lymphedema.
- KFDA approval (South Korea).
- Commercially available now in the US, Europe, South Korea and Middle East.
* BioBridge has not been approved by the FDA for treatment of lymphedema.
Nanoweave® Technology
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means to precisely print 3D scaffolding in such a way that mimics human tissue nano structure and directly influence the body’s repair function.
Grants, Awards, Partners and Collaborators
Fibralign has been recognized for its vision and potential to impact lives globally.
We are supported in our mission by world class partners and collaborators.
